EUCTR2006-006523-40-SE进行中（未招募）不适用
A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis patients with chronic renal anaemia. - Umbrella
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Roche AB
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent
- •- Age 18 years or older
- •- Chronic renal anaemia
- •- Haemoglobin concentration between 10.5 g/dl and 12.5 g/dl
- •- Adequate iron status (serum ferritin >100 ng/mL AND TSAT>20% OR hypochromic red cells <10%)
- •- Continuous subcutaneous maintenance darbepoetin alfa therapy with the same dosing interval during the previous 2 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Transfusion of red blood cells during the previous 2 months
- •- Poorly controlled hypertension, i.e. sitting blood pressure exceeding 170/100 despite medication requiring hospitalization or interruption of darbepoetin alfa treatment in the previous 6 months
- •- Significant acute or chronic bleeding such as overt gastrointestinal bleeding
- •- Active malignant disease (except non-melanoma skin cancer)
- •- Haemolysis
- •- Haemoglobinopathies (e.g homozygous sickle-cell disease, thalassemia of all types)
- •- Folic acid deficiency
- •- Vitamin B12 deficiency
- •- Platelet count >500 x 109/L or <100 x 109/L
- •- Pure red cell aplasia
- •- Epileptic seizure during previous 6 months
- •- Congestive heart failure (NYHA Class IV)
- •- Myocardial infarction or stroke, severe or unstable coronary artery disease, severe liver disease during the previous 3 months
- •- Uncontrolled or symptomatic secondary hyperparathyroidism
- •- Pregnancy or lactation period
- •- Women of childbearing potential without effective contraception
- •- Participation in a clinical trial or receipt of an investigational compound or an investigational treatment during the previous 3 months
- •- Planned (date) elective surgery during the study period except for
- •- cataract surgery
- •- vascular access surgery
- •- Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication
研究者
相似试验
已完成
4 期
A Clinical Trial to assess the effect, safety and tolerability of MIRCERA administered intravenously two weekly for treating the chronic renal anaemia in dialysis patients who are not receiving ESA treatment currentlyCTRI/2009/091/000452Roche Products India Pvt Ltd India220
进行中（未招募）
不适用
A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of intravenous C.E.R.A. for the maintanance of haemoglobin levels in dialysis patients with chronic renal anaemia. - STABIChronic renal anaemiaMedDRA version: 9.1Level: LLTClassification code 10058123Term: Renal anaemiaEUCTR2007-002380-27-CZRoche s.r.o.200
已完成
不适用
Single arm open-label study to evaluate efficacy and safety of low intensity extracorporeal shockwave therapy in prostate cancer patients with ED after radical prostatectomyErectile dysfunctionJPRN-UMIN000022514Hiroshima University50
尚未招募
4 期
A study to assess the efficiency of Asthishrunkala upanaha (herbal poultice) in Janu Sandhigata Vata vis-Ã -vis osteoarthritis knee joint.CTRI/2019/07/019974Rajiv Gandhi University Of Health Sciences Karnataka
招募中
4 期
Effect of injection iron in improving haemoglobin level among pregnant womeCTRI/2017/09/009720All India Institute of Medical Sciences75